Peptide Based Cancer Therapeutics Market Expected to Reach USD 17.18 Billion by 2027, Registering a CAGR of 9.1%
The global peptide based cancer therapeutics market was valued at USD 8.58 billion in 2019 and is expected to grow at a CAGR of 9.1% during the 2020–2027 forecast period, according to Polaris Market Research. The market is projected to reach USD 17.18 billion by 2027. Peptide-based treatments are attracting attention in oncology because they combine low toxicity with high target selectivity, qualities that matter as the industry looks for alternatives to conventional cancer therapeutics.
Market Growth and Industry Outlook
Polaris Market Research identifies several factors behind the growth of the peptide based cancer therapeutics market: innovations in peptide based cancer treatment approaches, the growing prevalence of different types of cancer, high efficacy, and increased interest from pharmaceutical companies in research and development. In comparison with conventional options, peptide-based drugs are described as more cost effective, with a higher efficacy rate and specificity and lower toxicity.
Conventional cancer therapeutics are limited by a lack of tumor selectivity and the risk of severe side effects, while growing resistance among patients has intensified the search for new applications. Pharmaceutical companies are aware of the commercial potential of these peptides, and research efforts are likely to gain momentum during the assessment period.
Key Market Drivers and Emerging Trends
Scientific progress is a defining theme. Recent computing advancements in genomic research and bioinformatics have enabled the discovery of a new antigen-derived personalized vaccine, a development that favors the market’s future growth. Combination therapies that pair peptide therapies with check-point inhibitors are also likely to improve patient outcomes, another factor supporting the market’s trajectory.
Peptide based cancer therapeutics are described as precision-based personalized medicine, and because conventional radiotherapies are significantly costlier, biotechnology companies have found it imperative to develop novel therapeutics. Challenges that have hindered widespread adoption include high manufacturing cost, limited oral bioavailability, and low resistance to cleavage by serum proteases.
𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞:
https://www.polarismarketresearch.com/industry-analysis/peptide-based-cancer-therapeutics-market
Segment and Application Insights
The market is segmented by drug type, cancer type, mode of mechanism, distribution channel, and region. By drug type, the categories are Goserelin, Bortezomib, Leuprorelin, and others, and Bortezomib accounted for the largest share in 2019. Polaris Market Research links the segment’s position to higher drug sales, high efficacy, and low side effects.
By cancer type, the market covers lung, breast, colorectal, prostate, skin, and stomach cancer. In 2019, lung cancer accounted for the majority of the share and is likely to maintain it over the study period. The report cites air pollution, occupational exposure to asbestos and silica, and smoke as primary causes. According to WHO statistics referenced on the page, lung cancer accounted for 1.8 million deaths across the globe in 2018.
The remaining segmentation covers mode of mechanism, spanning inhibitory, necrosis-inducing, and pro-apoptotic categories, and distribution channel, which includes hospital, retail, and online pharmacies.
Regional Market Perspective
North America is the largest revenue contributor, followed by Europe and the Asia Pacific region. Rising cancer incidence in the United States is a key demand factor: according to the American Cancer Society and the National Center for Health Statistics, around 1,688,780 cancer cases were recorded in 2017, increasing demand for treatment solutions such as peptide based cancer therapeutics.
In Asia Pacific, personalized medicine has gained significant traction, and emerging economies are expected to provide a crucial impetus given the increased prevalence of cancer in China, Japan, South Korea, and India. In China, WHO statistics for 2015 recorded 1.7 million cases of lung cancer out of 8.9 million total cancer cases.
In Latin America, the disease burden is shifting from infectious diseases toward chronic diseases such as cancer. Research by the American Cancer Society notes that in Argentina and Brazil, more than 70 percent of cancers are diagnosed at an end stage, a pattern linked to the lack of basic planning tools such as cancer registries and treatment guidelines.
Competitive Landscape
The market includes both small and large participants. Key players named by Polaris Market Research are AstraZeneca PLC, Abbott, Allergan plc, Teva Pharmaceuticals, Pfizer Inc., Takeda Pharmaceutical, Amgen, Inc., Johnson & Johnson, AbbVie Inc., and Valeant Pharmaceuticals Inc. The competitive picture is shaped by pharmaceutical research and development interest in peptide-based drugs and by manufacturing and bioavailability challenges.
Future Market Outlook
Looking toward 2027, the peptide based cancer therapeutics market is forecast to rise from USD 8.58 billion in 2019 to USD 17.18 billion at a 9.1% CAGR. Continued work on the antigen-derived personalized vaccine, combinations involving check-point inhibitors, and the established position of Bortezomib among drug types point to a market where innovation and clinical need are closely linked. Manufacturing cost and bioavailability remain the hurdles identified in the report.
More Trending Latest Reports By Polaris Market Research:
Low-speed electric vehicle (LSEV) Market
Open Radio Access Network (Open RAN) Market
Self-Sustaining Smart Farms Market
English
French
Spanish
Turkish
Italiano
Russian